【摘要】 目的研究利培酮治疗精神分裂症时的血药浓度与疗效及副反应之间的相关性,从而确定利培酮更安全、有效的治疗窗。方法对52例精神分裂症患者,男28例,女24例,在利培酮治疗前及治疗后评定PANSS,TESS,ESRS。采用HPLC方法在治疗后4、8周测定利培酮的血药浓度。结果利培酮(2~8mg/d)治疗4、8周的血药浓度分别为(37.68±15.26)nmol/l和(49.21±16.23)nmol/l。利培酮的血药浓度与PANSS,TESS,ESRS显著相关,但当利培酮的血药浓度大于65nmol/l时,增加剂量疗效并不显著,反而使副反应增大。结论利培酮治疗精神分裂症时,其剂量在(2~6)mg/d,血药浓度在(30~65)nmol/l时更安全有效。更多还原

【Abstract】 Objective To study the relationship between serum concentration of risperidone and clinical effects and side effects in treatment of patients with schizophrenia,and to determine the treatment range of risperidone.MethodsA total of 52 schizophrenic inpatients (28 male, 24 female) were evaluated before and after treatment with PANSS,TESS,ESRS.HPLC was used to measure the concentration of risperidone at week 4,8 after treatment with risperidone.ResultsThe serum concentrations at week 4,8 after treatment with risperidone (2~8mg/d) were (37.68±15.26)nmol/l and (49.21±16.23)nmol/l. Serum concentration of risperidone was significantly related to PANSS,TESS,ESRS.When serum concentration of risperidone was over 65nmol/l, clinical effects did not improve with the increased dosage,but the side effects increased.ConlusionRisperidone is safe and effective when the drug dosage is (2~6)mg/d and serum concentration is (30~65)nmol/l.更多还原